GlaxoSmithKline revealed sales of a key treatment against a potential flu pandemic have rocketed since January – on the day a new outbreak of bird flu was confirmed in the UK.
The pharmaceuticals giant said sales of its anti-viral Relenza drug totalled £7m (€10m) in the first three months of this year – compared with £5m (€7.2m) for the whole of 2005.
Fewer than a million packs of Relenza were produced last year and Glaxo aims to ramp up production by 15 times to meet demand for more protection against flu viruses.
BTA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
